Atlas Trials

Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC

Clinical trial NCT03402464 · UNKNOWN

Trial details

NCT number
NCT03402464
Sponsor
Peking University Cancer Hospital & Institute
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma
Start date
2018-01-01
Primary completion
2019-06-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.